David Hulcoop
@davidhulcoop
Executive Director Open Targets. I lead Open Targets bringing industry and academia together around drug target ID and prioritisation. All views my own.
ID: 778682749485850624
21-09-2016 19:50:09
401 Tweet
344 Followers
493 Following
One more week to apply! Come join us in Human Technopole if you are interested in B cell biology, CRISPR screens and immunogenomics.
We welcome Julio Saez-Rodriguez Julio Saez-Rodriguez as our new Head of Research! Associate Director for EMBL-EBI Services Jo McEntyre Jo McEntyre has been promoted to Deputy Director of EMBL-EBI & Rolf Apweiler is stepping back to Associate Director as he looks towards retirement.
Join us for these exciting projects using Large Language Models and knowledge graphs, building on biocypher.org, within Open Targets led by Sebastian Lobentanzer 🕸
📢 On World #IBD Day weekend Carl Anderson and I are delighted to introduce Open-IBD! £11M funding from Open Targets and Wellcome Sanger Institute Open-IBD will study serial multi-omics and longterm outcomes from diagnosis in 1,000 people with IBD More👇 opentargets.org/news/open-ibd-…
New paper from ludovic vallier is online. "Acquisition of epithelial plasticity in human chronic liver diseases". Amazing work from Chris Gribben and Vasileios Galanakis in collaboration with Irina Mohorianu and Mike Alison. Few key points: 1/ link.springer.com/article/10.103…
Genetic evidence halves the odds of early clinical trial stoppage 🧬💊 Published today in Nature Genetics, Olesya Razuvayevskaya trained a machine learning classifier to analyse the free-text reasons explaining why 28,842 clinical trials stopped 3 key points: nature.com/articles/s4158…
Open Targets meets David Van Heel of Genes & Health! Genes&Health is a health research study of British-Bangladeshi and Pakistani-origin volunteers, ethnicities which are missing from many clinical trials and cohorts Thank you David for fascinating insights into this research!
Why do clinical trials stop? Researchers from Open Targets and EMBL-EBI have developed a machine learning model to analyse clinical trial data. They found a correlation to suggest that trials less supported by genetic evidence are more likely to fail. ebi.ac.uk/about/news/res…